[go: up one dir, main page]

MX2024005945A - Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos. - Google Patents

Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.

Info

Publication number
MX2024005945A
MX2024005945A MX2024005945A MX2024005945A MX2024005945A MX 2024005945 A MX2024005945 A MX 2024005945A MX 2024005945 A MX2024005945 A MX 2024005945A MX 2024005945 A MX2024005945 A MX 2024005945A MX 2024005945 A MX2024005945 A MX 2024005945A
Authority
MX
Mexico
Prior art keywords
fusion proteins
engineered polypeptides
polypeptides
serum albumin
complement component
Prior art date
Application number
MX2024005945A
Other languages
English (en)
Inventor
Douglas L Sheridan
Paul P Tamburini
Bridget Puffer
Julian Chandler
Nimish Gera
Siddharth Jindal
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2024005945A publication Critical patent/MX2024005945A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La descripción proporciona polipéptidos modificados que se unen específicamente al componente del complemento humano C5 y/o albúmina sérica. La descripción también proporciona proteínas de fusión que comprende esos polipéptidos modificados, donde esas proteínas de fusión pueden ser proteínas de fusión multivalentes o multiespecíficas. La descripción proporciona además moléculas de ácido nucleico que codifican para esos polipéptidos modificados o proteínas de fusión y métodos para producir esos polipéptidos modificados o proteínas de fusión. La descripción proporciona además composiciones farmacéuticas que comprenden esos polipéptidos modificados o proteínas de fusión y métodos de tratamiento usando esos polipéptidos modificados o proteínas de fusión.
MX2024005945A 2017-07-11 2020-01-08 Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos. MX2024005945A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762531215P 2017-07-11 2017-07-11

Publications (1)

Publication Number Publication Date
MX2024005945A true MX2024005945A (es) 2024-06-11

Family

ID=63036501

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2024005946A MX2024005946A (es) 2017-07-11 2020-01-08 Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.
MX2024005945A MX2024005945A (es) 2017-07-11 2020-01-08 Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2024005946A MX2024005946A (es) 2017-07-11 2020-01-08 Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.

Country Status (12)

Country Link
US (3) US11498960B2 (es)
EP (1) EP3625265A1 (es)
JP (3) JP7684803B2 (es)
KR (3) KR102806328B1 (es)
CN (3) CN111201246B (es)
AU (3) AU2018301412B2 (es)
BR (1) BR112019028269A2 (es)
CA (1) CA3067247A1 (es)
CO (1) CO2020000369A2 (es)
IL (3) IL307197B1 (es)
MX (2) MX2024005946A (es)
WO (1) WO2019014360A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
US20210388070A1 (en) * 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
WO2020214679A1 (en) * 2019-04-16 2020-10-22 University Of Washington Amantadine binding protein
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
KR20220122608A (ko) 2019-12-26 2022-09-02 에자이 알앤드디 매니지먼트 가부시키가이샤 보체 c5의 발현을 저해하는 이중 가닥 리보핵산을 함유하는 약제학적 조성물
WO2021144962A1 (ja) 2020-01-17 2021-07-22 オリンパス株式会社 発光装置、および駆動装置
US20230416344A1 (en) 2020-04-16 2023-12-28 Alexion Pharmaceuticals, Inc. Methods for treating a complement mediated disorder caused by viruses
US20230357442A1 (en) * 2020-10-05 2023-11-09 Alexion Pharmaceuticals, Inc. Methods of treating dermatomyositis
TW202417490A (zh) * 2022-08-31 2024-05-01 美商艾力克森製藥公司 用於治療鐮狀細胞病的融合多肽之劑量及投與
CN116731149B (zh) * 2023-06-07 2024-02-27 华中农业大学 草鱼补体活化分子碳末端肽C5a-CP及应用
CN119241699B (zh) * 2024-09-24 2025-11-28 广州康盛生物科技股份有限公司 一种抗人补体c5的单域抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE69738166T2 (de) 1996-06-27 2008-06-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren
AU2152299A (en) 1997-10-27 1999-05-24 Unilever Plc Multivalent antigen-binding proteins
ATE422369T1 (de) 1999-12-24 2009-02-15 Genentech Inc Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen
DE60143544D1 (de) * 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
AU2003283137B8 (en) * 2002-11-08 2010-07-29 Ablynx N.V. Camelidae antibodies against immunoglobulin E and use thereof for the treatment of allergic disorders
MXPA05006043A (es) 2003-01-10 2006-01-30 Ablynx Nv Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas.
AU2012254935B2 (en) * 2004-02-12 2014-05-29 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
BRPI0511755A (pt) 2004-06-01 2008-01-02 Domantis Ltd composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN100368022C (zh) 2005-09-20 2008-02-13 中国人民解放军第二军医大学 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法
WO2007045465A1 (en) * 2005-10-21 2007-04-26 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
NZ594285A (en) 2005-11-04 2013-02-22 Genentech Inc USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
US8435512B2 (en) 2008-03-03 2013-05-07 Novelmed Therapeutics, Inc. Anti-properdin antibodies
SI2328616T1 (sl) * 2008-08-05 2015-08-31 Novartis Ag Sestavki in postopki za protitelesa proti komplementnemu proteinu C5
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
IN2012DN01663A (es) 2009-09-16 2015-06-05 Immunomedics Inc
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
JP2013518853A (ja) * 2010-02-05 2013-05-23 アブリンクス エン．ヴェー． 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
AU2011224224B2 (en) 2010-03-10 2015-07-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP2590993B1 (en) 2010-07-09 2015-05-06 Affibody AB Polypeptides
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
AU2012279288B2 (en) 2011-07-01 2017-07-20 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
EP3330288A1 (en) 2011-12-21 2018-06-06 Novartis AG Compositions and methods for antibodies targeting factor p
WO2013102123A2 (en) 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
DK2817329T3 (en) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polypeptides Binding to Human Complement Component C5.
CA2887050A1 (en) 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
JP6767865B2 (ja) 2013-08-28 2020-10-14 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合する安定なポリペプチド
MY176200A (en) 2013-08-28 2020-07-24 Affibody Ab Binding polypeptides having a mutated scaffold
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
MX2019008827A (es) * 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão

Also Published As

Publication number Publication date
IL271920B1 (en) 2023-11-01
AU2018301412B2 (en) 2025-08-07
KR102806328B1 (ko) 2025-05-14
JP2025118590A (ja) 2025-08-13
IL271920B2 (en) 2024-03-01
IL271920A (en) 2020-02-27
WO2019014360A1 (en) 2019-01-17
IL324119A (en) 2025-12-01
JP7684803B2 (ja) 2025-05-28
CN117327188A (zh) 2024-01-02
BR112019028269A2 (pt) 2020-07-14
KR20250099285A (ko) 2025-07-01
AU2018301412A9 (en) 2025-08-07
CN111201246B (zh) 2023-10-27
AU2025200313A1 (en) 2025-02-13
JP2023120208A (ja) 2023-08-29
RU2020102910A (ru) 2021-08-11
CN111201246A (zh) 2020-05-26
US11498960B2 (en) 2022-11-15
WO2019014360A8 (en) 2019-02-21
KR20200026264A (ko) 2020-03-10
CO2020000369A2 (es) 2020-01-31
AU2018301412A1 (en) 2020-01-30
AU2025200303A1 (en) 2025-02-13
EP3625265A1 (en) 2020-03-25
CA3067247A1 (en) 2019-01-17
JP2020532285A (ja) 2020-11-12
RU2020102910A3 (es) 2021-12-02
US20250163138A1 (en) 2025-05-22
IL307197B1 (en) 2025-11-01
MX2024005946A (es) 2024-06-11
US12221473B2 (en) 2025-02-11
CN117327187A (zh) 2024-01-02
US20200399351A1 (en) 2020-12-24
KR20250068795A (ko) 2025-05-16
IL307197A (en) 2023-11-01
US20230235033A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
MX2024005945A (es) Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.
PH12019500596A1 (en) Recombinant binding proteins and their use
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
HK1258509A1 (zh) Gitr激动剂
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
WO2015109124A3 (en) Immunomodulatory agents
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
EA201892774A1 (ru) Антитела
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
MY191944A (en) Binding proteins and methods of use thereof
PH12019500571A1 (en) Anti-pd-1 antibodies
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
MX390894B (es) Polipéptido de fusión anti-cáncer.
PH12018501025A1 (en) Improved tnf binders
AU2018277310A1 (en) Aggrecan binding immunoglobulins
WO2016172551A3 (en) Methods of identifying bacteria comprising binding polypeptides
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
EA201591898A1 (ru) Антитела, направленные на m-csf
WO2016040767A3 (en) Chrdl-1 epitopes and antibodies